Does Melanotan 2 work without sun?

The mechanism does not require UV — MC1R activation drives eumelanin synthesis directly. The licensed analogue afamelanotide increases melanin density in patients who avoid sunlight entirely. How much pigmentation MT-2 produces without UV has never been measured in a controlled trial.

Does Melanotan 2 actually work?

Its receptor pharmacology is well characterised and it is a potent melanocortin agonist. The contested part is not whether it affects pigmentation but what else it does, since it is non-selective and also engages MC3R, MC4R and MC5R.

Do you still need UV with a melanocortin agonist?

Not for the mechanism. UV acts upstream of the receptor, so an agonist bypasses that step rather than depending on it.

MT-2 (Melanotan II)

Does Melanotan 2 Work Without UV?

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-314 cited sources

Mechanistically it does not need UV. MT-2 activates MC1R directly, and MC1R activation drives eumelanin synthesis whether or not ultraviolet light is present. The approved analogue afamelanotide demonstrates exactly that in licensed use. What has never been established for MT-2 itself is how much pigmentation results without UV, because no controlled trial has measured it.

Key facts

Mechanism: MC1R agonism, UV-independent
Downstream: cAMP, MITF, tyrosinase, eumelanin
Proof of principle: Afamelanotide, without UV
Controlled MT-2 data: None
MT-2 regulatory status: Not authorised

Why UV is not part of the mechanism

Ultraviolet light tans skin by damaging DNA, which triggers p53 signalling and the release of alpha-MSH, which then binds MC1R. MC1R activation raises cyclic AMP, which drives MITF and then tyrosinase, the rate-limiting enzyme in eumelanin synthesis. A melanocortin agonist enters that chain part-way down, at the receptor. Everything upstream — the UV, the DNA damage — is bypassed rather than required.

The approved analogue settles the principle

Afamelanotide, marketed as Scenesse, is a licensed MC1R agonist given to patients with erythropoietic protoporphyria, a condition in which sunlight causes severe pain. Those patients avoid light. Melanin density still rises. That is about as clean a demonstration as the question admits: MC1R agonism increases pigmentation without UV exposure driving it.

Research material referenced

MT-2 10mg — third-party HPLC tested

View — £19.99

What that does not establish about MT-2

Afamelanotide is a different molecule, given as a controlled-release implant, at a characterised dose, under supervision. MT-2 is a different analogue with broader receptor activity, and no controlled trial has measured pigmentation response in the absence of UV for it. Reasoning from one to the other gives you a plausible expectation, not a measured result — and the older human work on MT-2 generally paired it with UV exposure, which makes the two contributions impossible to separate in that literature.

So does it work at all

The receptor pharmacology is well characterised: MT-2 is a potent non-selective melanocortin agonist, and its design as a cyclic lactam was specifically intended to increase potency and resistance to degradation over native alpha-MSH. Whether it works is not really the contested question. What is contested is what it does alongside pigmentation, because non-selective means MC3R, MC4R and MC5R are engaged too, and that is where the reported adverse effects come from.

And the status of the compound

MT-2 is not an authorised medicine in the UK or the EU, and the MHRA has issued public warnings about melanotan products sold for human use. Material supplied for laboratory research is not supplied for administration to a person, and nothing above should be read as describing use in one.

Extended research context

The MT-2 (Melanotan II) deep dive

Deep dive: the identifier collision that points the wrong way

This site has now found several plausible-looking identifiers that resolve to the wrong molecule. A PubChem record for tirzepatide cited as retatrutide. Thymosin beta-4's CAS quoted as TB-500's. An unrelated organic acid returned for KPV. This one is the most consequential of the set, and the reason is direction. Searching PubChem for melanotan returns CID 16197727 - afamelanotide, at 1,646.8 Da for C78H111N21O19. That is Melanotan I, a linear thirteen-residue peptide, and it is an APPROVED MEDICINE, marketed as Scenesse for erythropoietic protoporphyria. Melanotan II is CID 92432: cyclic, seven residues, 1024.2 Da, 622 Da lighter, and assessed by no regulator anywhere. So the wrong record does not merely mislead about mass. It resolves from an unlicensed compound toward a licensed one, and the sequential naming - I and II - makes them look like versions of a single product rather than the structurally distinct compounds they are. Anyone verifying a certificate by searching the bare name lands on an approved drug's record and may never notice which compound it names.

Deep dive: four stability features in seven residues

PubChem's IUPAC name for CID 92432 is unusually complete and reads as a full specification: N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide, cyclic (2-7)-peptide. Unpack it and there are four independent protease-resistance features in a molecule of seven residues. A lactam bridge joins the aspartate side chain at position 2 to the lysine side chain at position 7, closing the ring - which both locks conformation for receptor engagement and eliminates the free termini exopeptidases require. Position 4 is D-phenylalanine, the mirror image of the natural form, and proteases are stereospecific enough that they largely cannot process it. The N-terminus is acetylated and the C-terminus amidated, capping both ends. And position 1 is norleucine, which is not among the twenty proteinogenic amino acids at all - so even setting aside the cyclisation and the D residue, this peptide could never have been a gene product. It is a fully synthetic construction rather than a modified natural sequence, and it is among the most chemically robust compounds in this catalogue as a direct result.

Deep dive: why the safety literature is included rather than omitted

There is a published dermatological literature here, and the editorial choice was to state it. Reid and colleagues documented atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013. Eijmael and colleagues published a risk review in the Nederlands Tijdschrift voor Geneeskunde in 2022 - a national medical journal considering the topic worth addressing directly. Case reports have a real limitation: they establish an observation without a denominator, so they cannot establish causation or incidence, which is the same constraint that applies to pharmacovigilance disproportionality signals. But that limitation cuts both ways. A case report is not proof of harm and it is not dismissible either. What makes the absence of better data significant here is that no regulator has assessed this compound - so there is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist for an injectable product simply does not, and what is available instead is what individual clinicians chose to publish after seeing something. Presenting the compound without that context would give an incomplete picture of what is actually known.

Research applications

▸Melanocortin receptor pharmacology and selectivity research
▸Cyclic peptide and lactam bridge design studies
▸D-amino acid substitution and protease resistance research
▸Structure-activity work on constrained peptide analogues
▸Comparative work on alpha-MSH derivatives
▸Analytical method development for cyclic peptides

Handling checklist

✓Verify against CID 92432, 1024.2 Da, C50H69N15O9, CAS 121062-08-6
✓Never verify by searching 'melanotan' alone - that returns afamelanotide at 1,646.8 Da
✓Require stereochemistry on the certificate - D-Phe4 is not detectable by mass
✓Protect from light; tryptophan at position 6 is photochemically reactive
✓Store lyophilised, cold, dry and dark
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine
✓Quantification at 280 nm is available thanks to the tryptophan

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'melanotan' to verify identity

Fix: That returns CID 16197727, afamelanotide, at 1,646.8 Da - an approved medicine and a different molecule. Use CID 92432 or search Melanotan II with the numeral.

✗ Treating Melanotan I and II as versions of one compound

Fix: They differ by 622 Da, by six residues, and by whether the peptide is cyclic or linear. Only Melanotan I has been assessed by regulators.

✗ Reading afamelanotide's approval as covering MT-2

Fix: Different molecule, different structure, different evidence, different assessment. Nothing transfers.

✗ Accepting a sequence written without stereochemistry

Fix: L- and D-phenylalanine have identical mass. A peptide with the L form at position 4 is a different compound that mass spectrometry cannot distinguish.

✗ Assuming a non-selective agonist affects only its intended receptor

Fix: Five melanocortin receptors share binding surfaces across different tissues. Engagement elsewhere is the same pharmacology in another place, not a side reaction.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Does Melanotan 2 work without sun?: The mechanism does not require UV — MC1R activation drives eumelanin synthesis directly. The licensed analogue afamelanotide increases melanin density in patients who avoid sunlight entirely. How much pigmentation MT-2 produces without UV has never been measured in a controlled trial.
Does Melanotan 2 actually work?: Its receptor pharmacology is well characterised and it is a potent melanocortin agonist. The contested part is not whether it affects pigmentation but what else it does, since it is non-selective and also engages MC3R, MC4R and MC5R.
Do you still need UV with a melanocortin agonist?: Not for the mechanism. UV acts upstream of the receptor, so an agonist bypasses that step rather than depending on it.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MT-2 (Melanotan II) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum